Form 4: AbbVie Director Edward J. Rapp Reports Stock Transactions

AbbVie Inc. director Edward J. Rapp has reported transactions related to stock equivalent units, reflecting his compensation and beneficial ownership.

Summary

• Edward J. Rapp, a Director at AbbVie Inc. (ABBV), has filed a Form 4 detailing transactions related to his beneficial ownership of company securities.
• The filing indicates that Mr. Rapp acquired 155 stock equivalent units on March 31, 2026, with a value of $217.49 per unit.
• These stock equivalent units are part of his director compensation, credited to a grantor trust account.
• The units earn returns equivalent to AbbVie stock and are generally paid out in cash at age 65 or upon retirement from the board.
• Mr. Rapp's beneficial ownership following these transactions includes 28,865 units, with the balance including units acquired through dividend reinvestment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation transactions and does not contain new strategic information or significant financial performance indicators.

Positives

• Director compensation structure aligns with shareholder interests through stock equivalent units.
• Dividend reinvestment feature indicates continued accumulation of beneficial ownership.
• The transaction date of March 31, 2026, suggests a forward-looking plan for compensation.

Negatives

• The filing does not detail any negative financial performance or operational issues.
• No indication of any divestment or reduction in beneficial ownership by the director.

Risks

• Potential for stock price volatility affecting the value of stock equivalent units.
• The deferred payout structure means the ultimate cash realization is subject to future board service and age milestones.

Future Outlook

The stock equivalent units are designed to provide future cash payouts based on the performance of AbbVie stock and the director's continued service and age milestones.

Industry Context

StockSavvy.ai notes that the use of stock equivalent units for director compensation is a common practice in the pharmaceutical and biotechnology sectors, aligning executive and director interests with those of long-term shareholders by linking compensation to stock performance.

Related Party Transactions

• Director fees credited to a stock equivalent unit account under a grantor trust established by the director.

Stakeholder Impact

• Shareholders: The filing reinforces the alignment of director compensation with stock performance, a positive for shareholder value.
• Employees: Indirect impact through the company's compensation practices for its leadership.
• Creditors: No direct impact from this type of filing.

Next Steps

• Director fees will continue to be credited to the stock equivalent unit account.
• Payout of accumulated stock equivalent units is expected at age 65 or upon retirement from the board.

Key Dates

Keywords

Form 4, SEC Filing, AbbVie Inc., ABBV, Edward J. Rapp, Director, Stock Equivalent Units, Beneficial Ownership, Grantor Trust, Director Compensation